DivestmentOct 5, 2026, 04:22 PM
Standard BioTools Sells Microfluidics Business to ARCHIMED
AI Summary
Standard BioTools Inc. announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is anticipated to close within approximately 30 days, pending standard closing conditions. This divestment is described as another strategic step for Standard BioTools. The company also provided additional information regarding its proposed transactions with Treeline Biosciences, Inc. and the sale of its Mass Cytometry business to Element Biosystems, LLC.
Key Highlights
- Standard BioTools Inc. has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED.
- The transaction is expected to close in approximately 30 days, subject to customary closing conditions.
- The Microfluidics business will continue to operate as part of Standard BioTools until closing.
Price Impact
More from LAB